Decision

Promotion of Intrathecal Baclofen by Medtronic limited

Published 9 June 2021

SUMMARY REPORT FOR PUBLICATION

March 2021 Promotion of Intrathecal Baclofen by Medtronic limited

A member of the public complained about an advertisement that was shown on their LinkedIn feed about a generic Prescription Only Medicines (POM) to be used with an intrathecal injection device that could be viewed by members of the public in November 2020 by Medtronic Limited. The complainant alleged that POM was being promoted to the public, while linked pages were not clearly distinguished for Health Care Professionals.

MHRA upheld the complaint. Medtronic confirmed that they have put a hold on all promotional campaigns involving the SynchroMed II pump have removed the LinkedIn campaign including linked webpages within the campaign pages and are reviewing all current promotional materials and are reviewing patient webpages related to SynchroMed II pumps.